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Abstract: Chronic liver disease constitutes a growing public health issue worldwide, with no safe and
effective enough treatment clinical scenarios. The present review provides an overview of the current
knowledge regarding advanced chronic liver disease (ACLD), focusing on the major contributors of
its pathophysiology: inflammation, oxidative stress, fibrosis and portal hypertension. We present the
benefits of supplementation with docosahexaenoic acid triglycerides (TG-DHA) in other health areas
as demonstrated experimentally, and explore its potential as a novel nutraceutical approach for the
treatment of ACLD and portal hypertension based on published pre-clinical data.
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1. The Liver: Function and Cell Components
The liver is a dynamic and complex organ that is crucial for the regulation and homeostasis of
the organism. Both its size—as it is the largest organ of the human body—and its essential location
make it a centerpiece for many physiological processes. The liver is the only organ with a dual blood
supply: it receives oxygenated blood directly through the hepatic artery that derives from the celiac
artery, and nutrient-rich blood coming from the drainage of other visceral organs, such as the intestines,
through the portal vein [1]. Thus, it participates in many essential processes including macronutrient
metabolism, blood volume regulation, endocrine control of growth pathways, lipid and cholesterol
homeostasis and the processing of xenobiotic substances, among others [2].
1.1. The Hepatic Lobule
At the microscopic level, the liver is organized in hexagonal functional units called hepatic lobules.
A total of 80% of their volume is made up of hepatocytes, which constitute the liver parenchyma.
Hepatocytes carry out most hepatic metabolic and endocrine processes and are responsible for the
secretion of many products [3]. At each vertex of a hepatic lobule a portal triad is located, which
consists of the hepatic artery, the portal vein and biliary conducts, whereas at the center of the lobule is
the central vein. Bile is released by hepatocytes and flows through bile canaliculi towards the edges of
the hepatic lobule, where it is collected in the bile ducts. Blood, on the other hand, is provided by both
the hepatic arteriole, which supplies highly oxygenated blood, and the portal venule, which supplies
nutrient-rich blood. Blood from both origins is mixed together in a special capillary bed named hepatic
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sinusoid and flows towards the center of the lobule, where it is collected by the central vein [2,3].
Hepatocytes are lined up along the sinusoids, leaving the perisinusoidal space in between, also termed
the space of Disse. Into this space, hepatocytes extend their microvilli that take up the oxygen and
nutrients carried in the bloodstream while releasing metabolites and waste products. This leads to a
phenomenon called zonation: a gradient of blood composition and, consequently, of the processes
carried out by hepatic cells, between the outer and inner areas of the hepatic lobule. Even though
these gradients are flexible and may be altered depending on nutritional state, in general, hepatocytes
located in the outer zone will favor oxidative metabolism when compared to hepatocytes closer to the
central vein, while the latter have a higher capacity to absorb free fatty acids [4,5].
1.2. Sinusoidal Cell Components
These complex and well-balanced processes are possible thanks to the particular characteristics
of the hepatic sinusoids, which are highly permeable and specialized capillary vessels. They are
composed of several non-parenchymal cell types such as liver sinusoidal endothelial cells (LSEC),
hepatic stellate cells (HSC) and Kupffer cells (KC).
LSEC represent 15–20% of liver cells, but only 2.5% of its volume [6]. They form the endothelial
monolayer around the sinusoids. Unlike other endothelial cells, LSEC present specific characteristics
such as a lack of an organized basal membrane and the presence of transcytosolic pores of less than
200 nm in diameter called fenestrae. Those allow the circulation of oxygen, nutrients and other
products between the bloodstream and the liver parenchyma, while maintaining a certain barrier
function. Besides this key role, they also participate in other essential processes like inflammation,
endocytosis and vascular tone regulation [6–8].
HSC can be found in the space of Disse or perisinusoidal space, and present cytosolic prolongations
that confer them a star-shaped geometry. They represent 5–8% of hepatic cells [6]. In a healthy liver,
HSC are in a quiescent state. They store vitamin A in cytosolic lipid droplets, control retinoid
metabolism and regulate the growth and metabolism of neighboring cells, although they might
also participate in other processes that are still not fully understood. In the context of sustained
liver injury, HSC become activated, losing the vitamin A droplets and transdifferentiating into
fibroblasts. Under this phenotype, HSC exhibit increased contractility and migration, uncontrolled
proliferation and exacerbated extracellular matrix (ECM) deposition, being therefore responsible for
hepatic fibrosis [9–11].
Lastly, KC are liver resident macrophages. Under physiological conditions, they represent
around 6% of total liver cells [6]. Depending on the stimuli they detect, they can acquire a pro or
anti-inflammatory phenotype. KC play a key role in inflammation, phagocytosis, antigen presentation
and the secretion of soluble mediators [12].
2. Liver Disease: Relevance of ACLD and Portal Hypertension
Liver disease accounts for approximately 2 million deaths per year, constituting an important
clinical problem worldwide. Of those, 1.03 million deaths are due to advanced chronic liver disease
(ACLD) and its complications [13].
Chronic alcohol abuse [14], unhealthy dietary habits, such as those with a high content of fat
or fructose [15,16], and hepatitis B and C virus infection [17] are the three leading causes of chronic
liver disease (CLD). Even though the nature of these insults is different, when sustained over time
they all lead to a state of perpetual tissue inflammation, parenchymal cell death and exacerbated
deposition of ECM, ultimately causing hepatic fibrosis. Over the years, fibrosis can progress to
cirrhosis, which is characterized by the development of aberrant regenerative nodules and fibrotic
septa in the parenchyma, and even to hepatocellular carcinoma [18–20]. One of the most clinically
relevant syndromes associated with ACLD is portal hypertension, which is considered clinically
significant when the hepatic venous pressure gradient (HVPG)—an estimate of the pressure gradient
between the portal vein and the inferior vena cava—increases above 10 mmHg. Portal hypertension is
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directly related to the development of dreadful complications such as the formation of portal-systemic
collaterals, variceal bleeding, hepatic encephalopathy, ascites, jaundice, bacteremia, hypersplenism,
and hepatorenal syndrome, among others, and represents the first non-neoplastic cause of death and
the need for a liver transplantation in patients with ACLD [21].
From a clinical point of view, CLD progression can be classified into four stages: (1) compensated
cirrhosis without varices, (2) compensated cirrhosis with varices, (3) decompensated cirrhosis with
ascites, and (4) decompensated cirrhosis with variceal bleeding [20,22–24]. Very often, the first stages of
the disease are asymptomatic, and CLD is only detected once there is a decompensated cirrhosis with
severe portal hypertension (HVPG > 16 mmHg). This constitutes an additional challenge for therapy
development, as such advanced stages of cirrhosis are more difficult to reverse and constitute a higher
health risk. Indeed, despite extensive preclinical and clinical research in the last decades, current
therapeutic options for the treatment of portal hypertension are limited, with a lack of a safe and
effective enough treatment in clinical scenarios. Several therapeutic approaches have been—and are still
being—investigated, both at the pre-clinical and clinical levels, including antifibrotic, vasoprotective
and antioxidant strategies, among others [25–27]. However, liver transplantation remains a frequent
treatment option for patients with ACLD [13].
Moreover, changes in nutrition and life habits over the last decades, have caused a rise of
non-alcoholic fatty liver disease (NAFDL), with a worldwide prevalence of 25% in the general
population. In patients suffering from obesity, diabetes or other metabolic risk factors, the prevalence
of NAFLD is even higher, over 70% [28]. This is mainly caused by the increasing amounts of circulating
free fatty acids and the chronic low-grade inflammation observed in the white adipose tissue [29].
Approximately one third of NAFLD patients progress to non-alcoholic steatohepatitis (NASH), and,
as with other CLD etiologies, can ultimately develop cirrhosis and hepatocellular carcinoma [30].
Therefore, in spite of some encouraging advances, liver diseases leading to ACLD are increasingly
challenging for public health. For this reason, further research efforts are needed to improve the current
therapeutic landscape for ACLD.
3. Major Contributors of ACLD Pathophysiology
3.1. Inflammation
In physiological conditions, the liver can be exposed to pathogens carried in portal blood. Resident
KC are able to detect their presence through their surface toll-like and nod-like receptors (TLR, NLR),
and therefore constitute a first-line of defense for the liver.
During CLD, damaged parenchymal cells undergo apoptosis or necroapoptosis releasing signals
such as alarmins or damage-associated molecular patterns (DAMPs; Figure 1). KC are able to detect
these signals and initiate an inflammatory response, notably through a TLR4-mediated mechanism that
directly activates the canonical nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB)
signaling pathway [31,32]. Moreover, TLR activation in KC and HSC triggers monocyte recruitment to
the liver through an increase in chemokine C-C motif ligand 2 (CCL2) and chemokine C-X-C motif
ligand 1 (CXCL1) levels [33,34]. Those monocytes differentiate into macrophages and participate
in hepatic inflammation. Consequentially, not only are liver macrophages heterogeneous in their
origin, but they also exhibit distinct functions. While KC play a key role in initiating inflammation,
monocyte-derived macrophages are linked to chronic inflammation and fibrogenesis [35].
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Figure 1. Major contributors of advanced chronic liver disease pathophysiology. ACLD involves
a profound de-regulation of all hepatic cell types, including hepatocyte necroapoptosis, the shift of
hepatic macrophages towards a pro-inflammatory phenotype, hepatic stellate cell activation, and liver
sinusoidal endothelial cell capillarization. Altogether, these alterations contribute to a state of increased
inflammation and oxidative stress, leading to the development of fibrosis and, ultimately, portal
hypertension. ACLD, advanced chronic liver disease; DAMPs, damage-associated molecular patterns;
HSC, hepatic stellate cells; IHVR, intrahepatic vascular resistance; KC, Kupffer cells; LSEC, liver
sinusoidal endothelial cells; MMPs, metalloproteinases; PH, portal hypertension; ROS, reactive oxygen
species; TIMPs, tissue inhibitors of metalloproteinases.
In general, macrophages can acquire an M1 pro-inflammatory phenotype or an M2
anti-inflammatory phenotype. In response to pro-inflammatory stimuli, macrophages release cytokines,
such as tumor necrosis factor alpha (TNF-α) r interleukins (IL) IL-1β, IL-6, IL-12, IL-18, and chemokines,
that will, in turn, act as pro-inflammatory signals themselves. Said cytokines and chemokines can be
captured by the neighboring inflammatory cells, magnifying the ro-inflammatory response, or by
other cell types, giving rise to an intercellular cross-talk. M2-macrophages, n the other hand, secrete
anti-inflammatory cytokines and growth factors, such as IL-10, transforming growth factor-β (TGF-β),
platelet derived growth factor (PDGF) and epidermal growth factor (EGF), and participate in wound
healing [12,36,37]. Nonetheless, the dichotomic view of M1 versus M2 phenotypes is nowadays
considered a simplification of reality, as cells are usually exposed to a complex combination of pro-
and anti-inflammatory signals, giving rise to a whole spectrum of activation states and functions [38].
Besides macrophages, other inflammatory agents participate in the inflammatory response,
with neutrophils, dendritic cells and T-lymphocytes bei g the most relevant. Neutrophils are rapidly
recruited to the liver after parenchymal injury and contribute to CLD progression by releasing both
pro-inflammatory mediators and reactive oxygen and nitrogen species [39]. Furthermore, a recent study
linked the presence of neutrophil extracellular traps (NETs) to microvascular thrombosis and portal
hypertension in murine models of ACLD [40]. While dendritic cells’ and lymphocytes’ implications in
the pathophysiology of ACLD are not yet fully understood, it is believed that they promote hepatocyte
injury through the synthesis of inflammatory mediators or, in the case of T helpers 1, 2, 17 (Th1, Th2,
Th17) even by directly killing hepatocytes [39,41].
Finally, it is important to note that inflammation can have beneficial or detrimental effects
depending on the stage of the disease. Whereas in the early stages of CLD, chronic inflammation is
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mostly harmful, causing hepatocyte injury and fibrogenesis, and contributing to disease progression,
in advanced stages of liver disease it can have positive effects by fighting frequent bacterial infections
and stimulating liver regeneration [41].
3.2. Oxidative Stress
Reactive oxygen species (ROS) are highly chemically reactive molecules derived from oxygen
metabolism. They can be found as free radicals, such as the superoxide anion (O2−) and hydroxyl
radicals (OH−), or as non-radical forms, such as hydrogen peroxide (H2O2). ROS can be generated by
incomplete reduction of oxygen during respiration or as by-products of metabolic processes carried out
by enzymes like nitric oxidase synthase (NOS), nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase, cyclooxygenase (COX), or superoxide dismutase (SOD), among others [42]. Hepatocytes, HSC,
LSEC, and KC are all capable of generating ROS. At low levels, ROS participate in many physiological
processes, including intracellular messaging, regulation of cell growth, differentiation, and apoptosis.
Even under non-pathological conditions, the liver is often exposed to toxic substances present in portal
blood, causing an increase in ROS generation. For this reason, the antioxidant response in the liver is
essential and highly regulated to ensure homeostasis [43].
In CLD, increased inflammation, enzymatic de-regulation and mitochondrial damage lead to an
unbalance between ROS production and elimination through antioxidant mechanisms, causing their
accumulation (Figure 1). This gives rise to a state of oxidative stress, in which ROS participate in the
uncontrolled oxidation of lipids, proteins and DNA molecules, therefore causing severe cell damage.
In this manner, ROS cause parenchymal injury, even inducing hepatocyte death, and further contribute
to inflammation and CLD progression. ROS can also lead to the accumulation of reactive nitrogen
species (RNS), such as peroxynitrite anions (ONOO−), which can be equally damaging for the cells and
participate in many pathogenic processes [44–46]. Moreover, the presence of ROS can trigger signaling
cascades that affect transcriptional regulation, notably through nuclear factor erythroid 2-related
factor 2 (Nrf2). Some of these responses constitute homeostatic mechanisms against oxidative stress,
by inducing the expression of antioxidant agents (i.e., catalase, glutathione S-transferase, glutathione
peroxidase or heme oxygenase-1), but these fail to compensate for excessive ROS accumulation under
pathological conditions [47].
Furthermore, ROS can specifically activate signaling pathways in HSC and LSEC, promoting
fibrogenesis and increasing vascular tone. Particularly, in HSC, it has been suggested that ROS can
trigger c-Jun N-terminal kinase (JNK), NFκB, and TGF-β signaling pathways, increasing the expression
of collagen and other ECM components as well as pro-inflammatory mediators [48–51]. However, LSEC
are probably the most sensitive liver cell type to oxidative stress. In response to ROS accumulation,
they overexpress adhesion molecules, such as selectins, vascular cell adhesion molecule-1 (VCAM-1),
and intercellular adhesion molecule-1 (ICAM-1), secrete pro-inflammatory mediators, and can even
undergo autophagy as a mechanism to maintain homeostasis [6]. Moreover, in LSEC, the presence
of O2− contributes to the depletion of nitric oxide (NO) bioavailability, both through an increased
scavenging and a reduced synthesis of NO. On one hand, O2− reacts with NO producing ONOO−
while, at the same time, it inhibits endothelial NOS (eNOS) activation by reducing its phosphorylation
and increasing its inhibitors. This phenomenon favors the capillarization of LSEC and endothelial
dysfunction [44,52,53].
3.3. Fibrosis
Hepatic fibrosis is defined as the excessive accumulation of ECM proteins, such as collagen,
fibronectin or elastin, in the liver. It is a highly conserved response to tissue damage and exerts
beneficial effects in acute injury by preventing its propagation. However, when injury is sustained
over time, the fibrogenic response can become detrimental to the point of completely disrupting liver
parenchymal and vascular architecture [54].
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During CLD, in response to liver injury, inflammation, and oxidative stress, HSC become
activated and transdifferentiate from a quiescent state to an α-smooth muscle actin (α-SMA)-positive
myofibroblast-like cell (Figure 1). In their activated form, HSC exhibit increased proliferation,
contractility, migration and, most importantly, an exacerbated synthesis and deposition of ECM
components, constituting the main driver of hepatic fibrosis. There is a wide variety of signals and
pathways implicated in this phenomenon. However, two of the most central mechanisms of HSC
activation are the canonical TGF-β and PDGF signaling pathways [55]. In addition to an increased
ECM synthesis, fibrotic livers also present a decreased remodeling by metalloproteinases (MMPs),
further contributing to ECM accumulation. This is due both to a reduction of MMPs expression, and to
a decreased activity mainly through an overexpression of their specific inhibitors (TIMPs) [56].
With time, fibrosis can progress to cirrhosis, with the development of characteristic fibrous septa
surrounding areas of preserved parenchyma termed regeneration nodules. This level of architectural
distortion seriously hinders blood circulation through the liver and can entail major complications
such as portal hypertension [57]. Even though fibrosis was traditionally considered irreversible, it has
since been shown that, at early stages, complete resolution can be achieved. Even at advanced stages
of cirrhosis, a certain degree of regression is possible, markedly improving prognosis and, thus, raising
interest for anti-fibrotic therapies [27,58–61].
3.4. Portal Hypertension and Other Complications
ACLD is characterized by a profound de-regulation of all hepatic cell types. As mentioned
previously, hepatocytes undergo necroapoptosis, hepatic macrophages are polarized towards a
pro-inflammatory phenotype, LSEC experience capillarization, and HSC become activated and acquire
a pro-fibrogenic phenotype. Taken together, these alterations are responsible for the two main factors
leading to portal hypertension. On one hand is the structural component: fibrosis, vascular occlusion,
and the development of regeneration nodules contributing to the mechanical obstruction of blood flow
through the liver. On the other hand is the dynamic component: an unbalance between vasoconstrictor
and vasodilator synthesis, together with a higher sensitivity to vasoconstrictors, leading to sinusoidal
hypercontractility (Figure 1) [57,62].
According to Ohm’s law, ∆P = Q · R, the pressure gradient between two points in a fluidic system
(∆P or, in our case, HVPG) is given by the flow (Q) and the resistance of the system (R). During CLD’s
progression, the primary factor involved in the development of portal hypertension is an increase in
intrahepatic vascular resistance (IHVR), or R. Approximately, the structural and dynamic components
are responsible for 60% and 40% of said increase, respectively. As opposed to anti-fibrotic therapies,
which require a certain amount of time to exert noticeable effects, the dynamic component offers the
opportunity to acutely modulate portal pressure [63], constituting an attractive therapeutic target.
However, at more advanced stages of the disease, an increase in portal blood flow, or Q, takes place
due to mesenteric arterial vasodilation, contributing to the worsening of portal hypertension [64,65].
Lastly, portal hypertension entails a considerable number of severe health complications.
Approximately 50% of ACLD patients develop varices due to the diversion of up to 90% of portal flow
through portal-systemic collaterals. These enlarged and thin-walled vessels are extremely fragile and
can easily rupture, causing variceal hemorrhage [66,67]. Some complications of portal hypertension
arise from an increased gut permeability, which can lead to hepatic encephalopathy or other systemic
infections. Finally, other frequent complications include ascites, hepatorenal syndrome, splenomegaly
and hepatopulmonary syndrome.
4. TG-DHA as a Novel Nutraceutical Approach
4.1. TG-DHA’s Mechanism of Action and Demonstrated Benefits for the Human Health
ω-3 fatty acids are a family of essential polyunsaturated fatty acids (PUFAs) characterized by
the presence of a double bond three atoms away from their terminal methyl group. α-Linolenic acid
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(ALA) is the precursor of this family and can be converted, through a series of desaturation and
elongation reactions, to the more biologically active long-chainω-3 eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA). Although intake of ALA could theoretically be sufficient for EPA and
DHA synthesis, as the human body is able to carry out the subsequent reactions, ALA conversion
to ω-3 PUFAs has been reported to be actually very limited [68]. For this reason, ω-3 PUFAs must
be obtained from diet. Some of the most important dietary sources of ω-3 are species of fatty fish,
like mackerel, herring, salmon, tuna, and sardines, or the liver of some species of lean fish, such as
cod [69].
DHA is the end-product of the ω-3 synthesis pathway and, therefore, the most difficult to
obtain [70,71]. TG-DHA (triglycerides of DHA) in particular, present a higher intestinal absorption and
bioactivity when compared to similar dietary supplements, thanks to their triglyceride form and the
preservation of the cis structure of their double bonds. These characteristics confer TG-DHA a great
potential as a nutraceutical, both in healthy and diseased states. Indeed, DHA is highly pleiotropic
and participates in a wide range of physiological roles, from maintaining cardiovascular health to
constituting a structural component of the brain and central nervous system [72]. In particular, DHA
possesses strong anti-inflammatory and anti-oxidant effects. On one hand, it directly regulates key
transcription factors such as peroxisome proliferator-activated receptor gamma (PPAR) and NFκB,
inhibiting the expression of pro-inflammatory cytokines TNF-α, IL-1, IL-6, IL-8, and IL-12, inducible
NOS, and COX-2, as well as regulating metabolism. It can also bind to some G-protein coupled surface
receptors (GPR), such as GPR120, which is involved in anti-inflammatory signaling. Moreover, DHA
has been implicated in inflammation resolution by pro-resolving lipid mediators such as resolvins and
protectins, inhibition of eicosanoid synthesis, reduction of O2− levels, decreased lipid peroxidation,
and activation of antioxidant pathways [72–75]. TG-DHA, in particular, exhibits a high antioxidant
activity and has been patented for its use in cellular oxidative damage prevention [76].
Since inflammation and oxidative stress play a key role in many diseases’ pathophysiology’s,
TG-DHA constitutes a promising dietary supplement that could be used in very diverse medical
fields. In fact, TG-DHA has shown to exert beneficial effects in neurodegenerative diseases,
exhibiting a neuroprotective effect in experimental parkinsonism [77] and improving autoimmune
encephalomyelitis in mice [78]. Moreover, it has been reported to ameliorate macular function in
diabetic retinopathy [79], behavioral parameters in patients with attention-deficit hyperactivity disorder
(ADHD) [80], and even sperm quality by decreasing its DNA fragmentation [81].
4.2. TG-DHA in ACLD
In a previous publication from our research group [82], we found that ACLD’s pathophysiology
involves a profound deregulation of the hepatic fatty acid profile. The analysis, performed in livers
from healthy and cirrhotic rats, showed that, among other alterations, cirrhotic livers are markedly
depleted in DHA. In fact, they present an unbalance betweenω-3 andω-6 PUFAs that corresponds
to a pro-inflammatory phenotype, with increased arachidonic acid (AA)/DHA and AA/EPA ratios.
Interestingly, treating cirrhotic rats with TG-DHA reestablished a healthy fatty acid profile, including a
recovery of membrane characteristics and a shift to an anti-inflammatory phenotype (Figure 2).
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Based on TG-DHA’s beneficial effects on hepatic fatty acid profile, and given its anti-inflammatory
and anti-oxidant properties, we hypothesized that it could equally improve other aspects of ACLD.
Indeed, cirrhotic rats that received TG-DHA exhibited a significant improvement of portal hypertension
(−13.4% in portal pressure in vivo) without changes in portal blood flow, thus suggesting an amelioration
of IHVR. Reduction of portal pressure in such advanced stages of CLD is linked to a significant
improvement in prognosis [83], and is an indicator of underlying phenotypic ameliorations.
Subsequent analyses revealed that cirrhotic rats treated with TG-DHA presented reduced steatosis
and oxidative stress (measured as O2− levels in liver tissue). In agreement with these results,
a reduction in hepatic steatosis has been previously linked to long-chainω-3-driven oxidative stress
inhibition in an experimental model of high-fat diet [84]. TG-DHA-treated rats also exhibited reduced
inflammation, with lower hepatic macrophage infiltration and expression of key pro-inflammatory
cytokines. Furthermore, complementary in vitro studies performed with murine macrophages
evidenced that TG-DHA grants a protective effect against future inflammatory challenges, suggesting
a possible beneficial outcome of preventive or early-stage dietary supplementation.
HSC phenotype analysis revealed a significant deactivation, as well as a reduction of collagen
synthesis. However, TG-DHA failed to statistically significantly improve liver fibrosis, probably due
to insufficient ECM remodeling, underlining the necessity to extend the treatment period (of merely 2
weeks in this study) or to combine TG-DHA with complementary anti-fibrotic therapies. Moreover,
an unchanged structural component would suggest that portal hypertension improvement is related
to an amelioration of the dynamic component of ACLD, which is closely associated to oxidative stress
and inflammation. In fact,ω-3 PUFAs have been reported to ameliorate hepatic microcirculation in a
rat model of ischemia/reperfusion [85].
Lastly, HSC deactivation was confirmed in vitro in human LX2 cells, suggesting TG-DHA’s
translatability and encouraging its evaluation at the clinical scenario.
5. Future Perspectives
The current dietary trend, especially in western countries, favors the consumption ofω-6 over
ω-3 PUFAs, causing an unbalance between these two families of essential fatty acids that ultimately
leads to a state of increased oxidative stress and inflammation [72,86]. Given that ω-3 PUFAs are
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essential constituents of all human cells and possess an excellent safety profile, TG-DHA constitutes an
attractive nutraceutical product that can be used both in healthy and pathological contexts.
As in many other diseases, oxidative stress plays a key role in the pathogenesis of ACLD,
contributing to the deregulation of all hepatic cell types and the progression of fibrosis. Indeed, the use
of TG-DHA for the treatment of experimental ACLD has shown promising results [82]. However,
given the complexity of the disease, the therapeutic approach for ACLD has recently shifted from
monotherapy to combination therapy. While TG-DHA has already been combined with caffeine as a
strategy for the treatment of Parkinson’s disease [87], evaluating its combination with vasomodulator
or anti-fibrotic drugs would be of great interest for the treatment of ACLD and portal hypertension.
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